Eric Burks

MD

Boston University School Of Medicine

Associate Professor

NLST (Learn more about this study)

NLST-867

Jan 7, 2022

Pulmonary Adenocarcinoma of Low Malignant Potential

Overdiagnosis in the CTLS arm of the NLST was associated with bronchoalveolar carcinoma (BAC). There was no central pathologic review for the NLST and BAC represented an entity whose criteria had been multiply revised and inconsistently applied before ultimately being abandoned by the IASLC and WHO after the NLST publication. More recently, my group has defined histologic criteria associated with indolent lung adenocarcinoma behavior after complete resection. This entity is termed "pulmonary adenocarcinoma of low malignant potential" and in combination with adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) corresponded to a frequency similar to that of BAC among stage I adenocarcinoma in the CTLS arm of the NLST.

Yambayev I, Sullivan TB, Suzuki K, Zhao Q, Higgins SE, Yilmaz OH, Litle VR, Moreira P, Servais EL, Stock CT, Quadri SM, Williamson C, Rieger-Christ KM, Burks EJ. Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Am J Surg Pathol. 2021 Apr 1;45(4):567-576. PubMed PMID: 33177339.